Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Hepion Pharmaceuticals, Inc. (HEPA)

0.73   0.015 (2.08%) 03-22 11:39
Open: 0.7151 Pre. Close: 0.7151
High: 0.7364 Low: 0.7003
Volume: 20,406 Market Cap: 56(M)

Technical analysis

as of: 2023-03-22 11:16:48 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.92     One year: 1.02
Support: Support1: 0.66    Support2: 0.54
Resistance: Resistance1: 0.79    Resistance2: 0.87
Pivot: 0.76
Moving Average: MA(5): 0.72     MA(20): 0.76
MA(100): 0.58     MA(250): 0.65
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 21.7     %D(3): 24.5
RSI: RSI(14): 44
52-week: High: 1.33  Low: 0.25
Average Vol(K): 3-Month: 771 (K)  10-Days: 108 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ HEPA ] has closed above bottom band by 20.4%. Bollinger Bands are 34.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.74 - 0.75 0.75 - 0.75
Low: 0.69 - 0.7 0.7 - 0.7
Close: 0.71 - 0.72 0.72 - 0.72

Company Description

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Headline News

Thu, 16 Mar 2023
Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI ... - Yahoo Finance

Thu, 09 Mar 2023
Should You Add Hepion Pharmaceuticals Inc (HEPA) Stock to Your Portfolio Thursday? - InvestorsObserver

Thu, 02 Mar 2023
EPO Decision to Grant European Patent for Rencofilstat Further ... - GlobeNewswire

Thu, 02 Mar 2023
Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase 2 ... - GlobeNewswire

Wed, 01 Mar 2023
Do Traders Think Hepion Pharmaceuticals Inc (HEPA) Can Keep Climbing Wednesday? - InvestorsObserver

Mon, 27 Feb 2023
Will Hepion Pharmaceuticals Inc (HEPA) Stay at the Top of the Healthcare Sector? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 76 (M)
Shares Float 76 (M)
% Held by Insiders 0.1 (%)
% Held by Institutions 9.4 (%)
Shares Short 717 (K)
Shares Short P.Month 906 (K)

Stock Financials

EPS -0.57
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.75
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -30.9
Return on Equity (ttm) -55.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.59
Qtrly Earnings Growth 0
Operating Cash Flow -38 (M)
Levered Free Cash Flow -24 (M)

Stock Valuations

PE Ratio -1.27
PEG Ratio 0
Price to Book value 0.94
Price to Sales 0
Price to Cash Flow -1.45

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-06-02
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.